Drug firm Strides Arcolab today said it has received the US health regulator's nod to market Acarbose tablets, an anti-diabetic drug, in the American market.
The company has received approval from the US Food and Drug Administration (USFDA) for marketing of Acarbose tablets in strengths of 25 mg, 50 mg and 100 mg in the US market, Strides Arcolab said in a statement.
According to March, 2011, IMS data, the size of the US market for Acarbose tablets is around $21 million, with no Indian generic players in the market, it added.
"This product will be marketed and sold by Perrigo under a profit share partnership. The product is expected to be launched shortly, within Q3, 2011," the company said.
US-based Perrigo manufactures and markets over-the- counter drugs such as analgesics, cold medicines, antacids, laxatives and nutritional products.
Shares of Strides Arcolab were being quoted at Rs 369.05 apiece on the Bombay Stock Exchange in late afternoon trade, down 1.68% from their previous close.
